MESO vs NVAX: stock comparison and AI forecast
Mesoblast Ltd (MESO) and Novavax Inc (NVAX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MESO Mesoblast Ltd
- Price
- $14.77 -6.5% · 6M
- Market Cap
- $1.89B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVAX Novavax Inc
- Market Cap
- $1.66B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MESO is 1.1 times larger than NVAX by market capitalization ($1.89B against $1.66B).
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MESO | NVAX |
|---|---|---|
| Market Cap | $1.89B | $1.66B |
| EPS | $-0.25 | $-1.29 |
| Revenue/Share | $0.61 | $2.51 |
Profitability & Margins
| Metric | MESO | NVAX |
|---|---|---|
| ROA | – | -25.9% |
| ROIC | – | -37.5% |
| Gross Margin | – | 78.6% |
| Operating Margin | – | -56.6% |
| Net Margin | – | -59.9% |
| EBT Margin | -357.5% | -59.3% |
| Tax Rate | -0.3% | -1.0% |
Financial Health
| Metric | MESO | NVAX |
|---|---|---|
| Current Ratio | 1.58x | 2.33x |
| Quick Ratio | 1.41x | 2.30x |
| D/E Ratio | 0.36x | – |
| Financial Leverage | 1.36x | – |
| Interest Coverage | – | -12.1x |
| Working Capital | $74M | $441M |
Cash Flow
| Metric | MESO | NVAX |
|---|---|---|
| Operating Cash Flow | -$149M | -$37M |
Operational Efficiency
| Metric | MESO | NVAX |
|---|---|---|
| Asset Turnover | 0.10x | 0.43x |
| Receivables Turnover | 1.8x | 22.1x |
| Inventory Turnover | – | 8.8x |
| Fixed Assets Turnover | 43.3x | 10.8x |
| Days Sales Outstanding | 204 days | 17 days |
| Days Inventory | – | 41 days |
| Payables Period | – | 95 days |
| Cash Conversion Cycle | – | -37 days |
Income Statement
| Metric | MESO | NVAX |
|---|---|---|
| Total Revenue | $78M | $414M |
| Operating Income | – | -$234M |
| Net Income | – | -$248M |
| R&D Expense | $127M | $340M |
| SG&A Expense | – | $213M |
| Cost of Goods Sold | – | $89M |
Dividend & Shareholder Information
| Metric | MESO | NVAX |
|---|---|---|
| Shares Outstanding | 128M | 165M |
| Net Income Growth | – | -158.6% |
| EPS Growth | – | -197.0% |
MESO vs NVAX: stock comparison and AI forecast
Which is bigger, MESO or NVAX?
MESO is 1.1 times larger than NVAX by market capitalization ($1.89B against $1.66B).
Which one does Intratio's AI model rank higher, MESO or NVAX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.